ucsf logo

Thomas M. Link, MD, PhD

Diagnostic Radiology
Portrait of Thomas M. Link
Portrait of Thomas M. Link
ucsf logo

Thomas M. Link, MD, PhD

Diagnostic Radiology

On this page

About me

Dr. Thomas M. Link is chief of the musculoskeletal imaging section in the UCSF Department of Radiology and Biomedical Imaging. As clinical director of the department's Musculoskeletal Quantitative Imaging Research (MQIR) group, he has a strong interest in translational research (using study findings to establish new treatments or diagnostic methods). The main focuses of MQIR are: imaging of osteoporosis, particularly developing new techniques for assessing bone quality and density; applying new imaging techniques to the assessment of osteoarthritis and cartilage, and to preventing cartilage degeneration; new imaging sequences for musculoskeletal imaging at high field; and MR-guided high-intensity focused ultrasound for treatment of bony abnormalities.

Link earned his medical degree at Johannes Gutenberg University Mainz in Germany. He completed his medical residency in Münster, Germany. He completed a research fellowship in radiology at UCSF.

Link was a vice chair in the radiology department at the Technical University of Munich before joining UCSF in 2003.

Education & training

Board certification

  • Diagnostic Radiology, American Board of Radiology

Residency

  • Radiology, General, Muenster Memorial Hospital
  • Nuclear Medicine, KKH Hellersen -Teaching Hosp Univ of Bonn, Germany
  • Radiology, General, Zentrales Roentgeninstitut de Rheumakliniken

Internship

  • City Hospital Idar-Oberstein

Degree

  • MD, Johannes-Gutenberg Universitat Mainz

My expertise

Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.

For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.